Laboratory assays for diagnosis and management of hepatitis C virus infection

Journal of Clinical Microbiology

Volumn 40, Issue 12, 2002, Pages 4407-4412

  Richter, Sandra S ^a  

^a UNIVERSITY OF IOWA HEALTH CARE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; HEPATITIS C ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M ANTIBODY; INTERFERON; PEGINTERFERON ALPHA2A; RIBAVIRIN; VIRUS RNA;

ANTIBODY DETECTION; ANTIGEN DETECTION; BLOOD TRANSFUSION; BRANCHED DNA SIGNAL AMPLIFICATION ASSAY; CLINICAL FEATURE; CLINICAL TRIAL; DEVICE; DIAGNOSTIC ACCURACY; DISEASE COURSE; ENZYME IMMUNOASSAY; FOOD AND DRUG ADMINISTRATION; GENOTYPE; GEOGRAPHIC DISTRIBUTION; HEPATITIS C; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; INFECTION RISK; INTERMETHOD COMPARISON; INTRAVENOUS DRUG ABUSE; LABORATORY DIAGNOSIS; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK ASSESSMENT; RISK FACTOR; RNA ANALYSIS; SENSITIVITY ANALYSIS; SEROCONVERSION; SEROLOGY; SHORT SURVEY; VIRUS DETECTION; VIRUS TRANSMISSION;

HEPACIVIRUS; HEPATITIS C; HEPATITIS C ANTIBODIES; HUMANS; NUCLEIC ACID AMPLIFICATION TECHNIQUES; RNA, VIRAL; SEROLOGIC TESTS;

HEPATITIS C VIRUS; RNA VIRUSES;

EID: 0036899336     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.40.12.4407-4412.2002     Document Type: Short Survey

References (44)

1. Albadalejo, J., R. Alonso, R. Antinozzi, M. Bogard, A.-M. Bourgault, G. Colucci, T. Fenner, H. Petersen, E. Sala, J. Vincelette, and C. Young. 1998. Multicenter evaluation of the COBAS AMPLICOR HCV assay, an integrated PCR system for rapid detection of hepatitis C virus RNA in the diagnostic laboratory. J. Clin. Microbiol. 36:862-865.
2. Alter, H. 1999. Discovery of non-A, non-B hepatitis and identification of its etiology. Am. J. Med. 107(Suppl. 6B):16S-20S.
3. Alter, H. J. 1992. New kit on the block: Evaluation of second-generation assays for detection of antibody to the hepatitis C virus. Hepatology 15:350-353.
4. Barrera, J. M., B. Francis, G. Ercilla, M. Nelles, D. Achord, J. Darner, and S. R. Lee. 1995. Improved detection of anti-HCV in post-transfusion hepatitis by a third-generation ELISA. Vox Sang. 68:15-18.
5. Beld, M., R. Sentjens, S. Rebers, C. Weegink, J. Weel, C. Sol, and R. Boom. 2002. Performance of the new Bayer VERSANT HCV RNA 3.0 assay for quantitation of hepatitis C virus RNA in plasma and serum: Conversion to international units and comparison with the Roche COBAS Amplicor HCV Monitor, version 2.0, assay. J. Clin. Microbiol. 40:788-793.
6. Bendinelli, M., M. Pistello, F. Maggi, and M. Vatteroni. 2000. Blood-borne hepatitis viruses: Hepatitis B, C, D, and G viruses and TT virus, p. 306-337. In S. Specter, R. L. Hodinka, and S. A. Young (ed.), Clinical Virology Manual, 3rd Ed. ASM Press, Washington, D.C.
7. Bouvier-Alias, M., K. Patel, H. Dahari, S. Beaucourt, P. Larderie, L. Blatt, C. Hezode, G. Picchio, D. Dhumeaux, A. U. Neumann, J. G. McHutchison, and J.-M. Pawlotsky. 2002. Clinical utility of total HCV core antigen quantification: A new indirect marker of HCV replication. Hepatology 36:211-218.
8. Bukh, J., R. H. Purcell, and R. H. Miller. 1992. Importance of primer selection for the detection of hepatitis C virus RNA with the polymerase chain reaction assay. Proc. Natl. Acad. Sci. USA 89:187-191.
9. Centers for Disease Control and Prevention. 1998. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Morb. Mortal. Wkly. Rep. 47(RR-19):1-39.
10. Choo, Q.-L., G. Kuo, A. J. Weiner, L. R. Overby, D. W. Bradley, and M. Houghton. 1989. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244:359-362.
11. Davis, G. L. 1999. Hepatitis C virus genotypes and quasispecies. Am. J. Med. 107(Suppl. 6B):21S-26S.
12. European Association for the Study of the Liver Consensus Panel. 1999. European Association for the Study of the Liver International Consensus Conference on Hepatitis C. J. Hepatol. 30:956-961.
13. Fabrizi, F., F. F. Poordad, and P. Martin. 2002. Hepatitis C infection and the patient with end-stage renal disease. Hepatology 36:3-10.
14. Germer, J. J., P. J. Heimgartner, D. M. Ilstrup, W. S. Harmsen, G. D. Jenkins, and R. Patel. 2002. Comparative evaluation of the VERSANT HCV RNA 3.0, QUANTIPLEX HCV RNA 2.0, and COBAS AMPLICOR HCV MONITOR version 2.0 assays for quantification of hepatitis C virus RNA in serum. J. Clin. Microbiol. 40:495-500.
15. Gretch, D. R. 1997. Diagnostic tests for hepatitis C. Hepatology 26(3 Suppl. 1):43S-47S.
16. Halfon, P., P. Trimoulet, M. Bourliere, H. Khiri, V. De Ledinghen, P. Couzigou, J. M. Feryn, P. Alcaraz, C. Renou, H. J. A. Fleury, and D. Ouzan. 2001. Hepatitis C virus genotyping based on 5′ noncoding sequence analysis (Trugene). J. Clin. Microbiol. 39:1771-1773.
17. Jackson, J. B., K. Smith, C. Knott, A. Korpela, A. Simmons, E. Piwowar-Manning, S. McDonough, L. Mimms, and J. M. Vargo. 2002. Sensitivity of the Procleix HIV-1/HCV assay for detection of human immunodeficiency virus type 1 and hepatitis C virus RNA in a high-risk population. J. Clin. Microbiol. 40:2387-2391.
18. Kao, J.-H., M.-Y. Lai, Y.-T. Hwang, P.-M. Yang, P.-J. Chen, J.-C. Shen, T.-H. Wang, H.-C. Hsu, and D.-S. Chen. 1996. Chronic hepatitis C without antihepatitis C antibodies by second-generation assay: A clinicopathologic study and demonstration of the usefulness of a third-generation assay. Dig. Dis. Sci. 41:161-165.
19. Kim, W. R., R. S. Brown, N. A. Terrault, and H. El-Serag. 2002. Viral hepatitis: Hepatitis C. In Burden of liver disease in the United States: Summary of a workshop. Hepatology 36:227-242.
20. Kuo, G., Q.-L. Choo, H. J. Alter, G. L. Gitnick, A. G. Redeker, R. H. Purcell, T. Miyamura, J. L. Dienstag, et al. 1989. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science 244:362-364.
21. Lauer, G. M., and B. D. Walker. 2001. Hepatitis C virus infection. N. Engl. J. Med. 345:41-52.
22. Lee, J.-H., W. K. Roth, and S. Zeuzem. 1997. Evaluation and comparison of different hepatitis C virus genotyping and serotyping assays. J. Hepatol. 26:1001-1009.
23. Lee, S. C., A. Antony, N. Lee, J. Leibow, J.-Q. Yang, S. Soviero, K. Gutekunst, and M. Rosenstraus. 2000. Improved version 2.0 qualitative and quantitative AMPLICOR reverse transcription-PCR tests for hepatitis C virus RNA: Calibration to international units, enhanced genotype reactivity, and performance characteristics. J. Clin. Microbiol. 38:4171-4179.
24. Lee, S. S., E. J. Heathcote, K. R. Reddy, S. Zeuzem, M. W. Fried, T. L. Wright, P. J. Pockros, D. Haussinger, C. L. Smith, A. Lin, and S. C. Pappas. Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40KD). J. Hepatol., in press.
25. Lott, J. A., F. S. Nolte, D. R. Gretch, R. S. Koff, and L. B. Seeff. 2000. Laboratory guidelines for screening, diagnosis and monitoring hepatic injury, p. 21-23. In D. R. Dufour (ed.), Laboratory Medicine Practice Guidelines. National Academy of Clinical Biochemistry, Washington, D.C.
26. Manns, M. P., J. G. McHutchison, S. C. Gordon, V. K. Rustgi, M. Shiffman, R. Reindollar, Z. D. Goodman, K. Koury, et al. 2001. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomized trial. Lancet 358:958-965.
27. McHutchison, J. G., J. A. Shad, S. C. Gordon, T. R. Morgan, M.-H. Ling, J.-J. Garaud, J. K. Albrecht, and J. L. Dienstag. 2001. Predicting response to initial therapy with interferon plus ribavirin in chronic hepatitis C using serum HCV RNA results during therapy. J. Viral Hepat. 8:414-420.
28. McHutchison, J. G., S. C. Gordon, E. R. Schiff, M. L. Shiffman, W. M. Lee, V. K. Rustgi, Z. D. Goodman, M.-H. Ling, et al. 1998. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N. Engl. J. Med. 339:1485-1492.
29. National Institutes of Health Consensus Development Conference Panel. 1997. Management of hepatitis C. Hepatology 26(Suppl. 1):2S-10S.
30. Pawlotsky, J.-M. 1999. Diagnostic tests for hepatitis C. J. Hepatol. 31(Suppl. 1.):71-79.
31. Pawlotsky, J.-M., A. Bastie, C. Pellet, J. Remire, F. Darthuy, L. Wolfe, C. Sayada, J. Duval, and D. Dhumeaux. 1996. Significance of indeterminate third-generation hepatitis C virus recombinant immunoblot assay. J. Clin. Microbiol. 34:80-83.
32. Pawlotsky, J.-M., A. Fleury, V. Choukroun, L. Deforges, F. Roudot-Thoraval, P. Aumont, J. Duval, and D. Dhumeaux. 1994. Significance of highly positive c22-3 "indeterminate" second-generation hepatitis C virus (HCV) recombinant immunoblot assay (RIBA) and resolution by third-generation HCV RIBA. J. Clin. Microbiol. 32:1357-1359.
33. Pawlotsky, J.-M., I. Lonjon, C. Hezode, B. Raynard, F. Darthuy, J. Remire, C.-J. Sousy, and D. Dhumeaux. 1998. What strategy should be used for diagnosis of hepatitis C virus infection in clinical laboratories? Hepatology 27:1700-1702.
34. Pawlotsky, J.-M., L. Prescott, P. Simmonds, C. Pellet, P. Laurent-Puig, C. Labonne, F. Darthuy, J. Remire, et al. 1997. Serological determination of hepatitis C virus genotype: Comparison with a standardized genotyping assay. J. Clin. Microbiol. 35:1734-1739.
35. Pawlotsky, J.-M., M. Bouvier-Alias, C. Hezode, F. Darthuy, J. Remire, and D. Dhumeaux. 2000. Standardization of hepatitis C virus RNA quantification. Hepatology 32:654-659.
36. Poynard, T., P. Marcellin, S. S. Lee, C. Niederau, G. S. Minuk, G. Ideo, V. Bain, J. Heathcote, S. Zeuzem, C. Trepo, and J. Albrecht. 1998. Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 352:1426-1432.
37. Ross, R. S., S. O. Viazov, S. Hoffmann, and M. Roggendorf. 2001. Performance characteristics of a transcription-mediated nucleic acid amplification assay for qualitative detection of hepatitis C virus RNA. J. Clin. Lab. Anal. 15:308-313.
38. Sarrazin, C., D. A. Hendricks, F. Sedarati, and S. Zeuzem. 2001. Assessment, by transcription-mediated amplification, of virologic response in patients with chronic hepatitis C virus treated with peginterferon α-2a. J. Clin. Microbiol. 39:2850-2855.
39. Stramer, S. L., S. Caglioti, and D. M. Strong. 2000. NAT of the United States and Canadian blood supply. Transfusion 40:1165-1168.
40. Stuyver, L., R. Rossau, A. Wyseur, M. Duhamel, B. Vanderborght H. Van Heuverswyn, and G. Maertens. 1993. Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay. J. Gen. Virol. 74:1093-1102.
41. Tang, Y.-W., and D. H. Persing. 1999. Molecular detection and identification of microorganisms, p. 215-244. In P. R. Murray, E. J. Baron, M. A. Pfaller, F. C. Tenover, and R. H. Yolken, ed., Manual of Clinical Microbiology, 7th Ed. ASM Press, Washington, D.C.
42. Thio, C. L., K. R. Nolt, J. Astemborski, D. Vlahov, K. E. Nelson, and D. L. Thomas. 2000. Screening for hepatitis C virus in human immunodeficiency virus-infected individuals. J. Clin. Microbiol. 38:575-577.
43. Zanetti, A. R., E. Tanzi, and M. L. Newell. 1999. Mother-to-infant transmission of hepatitis C virus. J. Hepatol. 31(Suppl. 1):96-100.
44. Zein, N. N. 2000. Clinical significance of hepatitis C virus genotypes. Clin. Microbiol. Rev. 13:223-235.